PMID- 26714458
OWN - NLM
STAT- MEDLINE
DCOM- 20170713
LR  - 20220409
IS  - 1559-0100 (Electronic)
IS  - 1355-008X (Linking)
VI  - 52
IP  - 3
DP  - 2016 Jun
TI  - Systematic review and meta-analysis of vildagliptin for treatment of type 2 
      diabetes.
PG  - 458-80
LID - 10.1007/s12020-015-0841-1 [doi]
AB  - This systematic review and meta-analysis provides an update on the efficacy and 
      safety of vildagliptin for treatment of type 2 diabetes mellitus (T2DM). We 
      searched MEDLINE, COCHRANE, EMBASE and the drug manufacturer's website for 
      randomised controlled trials of vildagliptin in patients with T2DM. Sixty-nine 
      studies (28,006 patients) were included in the meta-analysis. Compared with 
      placebo vildagliptin reduced HbA1c (weighted mean difference WMD -0.69 %; 95 % CI 
      -0.83 to -0.56 %; I (2) = 82 %), and it was as effective as other antidiabetic 
      agents (WMD -0.01 %; 95 % CI -0.16 to 0.14 %; I (2) = 93 %), without increasing 
      the risk for hypoglycemia (OR 0.83; 95 % CI 0.59 to 1.16; I (2) = 0 % vs. 
      placebo, and OR 0.19; 95 % CI 0.15 to 0.24; I (2) = 78 % versus active 
      comparators). However, it was associated with an increase in the incidence of 
      arthralgia compared with other comparators (OR 1.23; 95 % CI 1.02 to 1.48; I 
      (2) = 0 %). On the contrary, vildagliptin did not increase the incidence of 
      pancreatitis (OR 0.97; 95 % CI 0.37 to 2.53; I (2) = 0 %), serious adverse events 
      (OR 0.98; 95 % CI 0.88 to 1.09; I (2) = 0 %) or death (OR 1.10, 95 % CI 0.75 to 
      1.61; I (2) = 0 %). Finally, odds ratio (OR) for heart failure, and overall 
      cardiovascular and cerebrovascular events was 0.77 (95 % CI 0.46 to 1.30; I 
      (2) = 0 %) and 0.91 (95 % CI 0.73 to 1.14; I (2) = 0 %), respectively. 
      Vildagliptin is an effective and safe therapeutic option for patients with T2DM, 
      both as monotherapy and as add-on treatment.
FAU - Bekiari, Eleni
AU  - Bekiari E
AD  - Clinical Research and Evidence-Based Medicine Unit, Second Medical Department, 
      Aristotle University Thessaloniki, Hippokratio General Hospital, 49 
      Konstantinoupoleos Street, 54642, Thessaloniki, Greece.
AD  - Diabetes Centre, Second Medical Department, Aristotle University Thessaloniki, 
      Thessaloniki, Greece.
FAU - Rizava, Chrysoula
AU  - Rizava C
AD  - Clinical Research and Evidence-Based Medicine Unit, Second Medical Department, 
      Aristotle University Thessaloniki, Hippokratio General Hospital, 49 
      Konstantinoupoleos Street, 54642, Thessaloniki, Greece.
FAU - Athanasiadou, Eleni
AU  - Athanasiadou E
AD  - Clinical Research and Evidence-Based Medicine Unit, Second Medical Department, 
      Aristotle University Thessaloniki, Hippokratio General Hospital, 49 
      Konstantinoupoleos Street, 54642, Thessaloniki, Greece.
FAU - Papatheodorou, Konstantinos
AU  - Papatheodorou K
AD  - Diabetes Centre, Second Medical Department, Aristotle University Thessaloniki, 
      Thessaloniki, Greece.
AD  - Second Medical Department, Democritus University Thrace, Alexandroupoli, Greece.
FAU - Liakos, Aris
AU  - Liakos A
AD  - Clinical Research and Evidence-Based Medicine Unit, Second Medical Department, 
      Aristotle University Thessaloniki, Hippokratio General Hospital, 49 
      Konstantinoupoleos Street, 54642, Thessaloniki, Greece.
FAU - Karagiannis, Thomas
AU  - Karagiannis T
AD  - Clinical Research and Evidence-Based Medicine Unit, Second Medical Department, 
      Aristotle University Thessaloniki, Hippokratio General Hospital, 49 
      Konstantinoupoleos Street, 54642, Thessaloniki, Greece.
FAU - Mainou, Maria
AU  - Mainou M
AD  - Clinical Research and Evidence-Based Medicine Unit, Second Medical Department, 
      Aristotle University Thessaloniki, Hippokratio General Hospital, 49 
      Konstantinoupoleos Street, 54642, Thessaloniki, Greece.
FAU - Rika, Maria
AU  - Rika M
AD  - Diabetes Centre, Second Medical Department, Aristotle University Thessaloniki, 
      Thessaloniki, Greece.
FAU - Boura, Panagiota
AU  - Boura P
AD  - Second Medical Department, Aristotle University Thessaloniki, Thessaloniki, 
      Greece.
FAU - Tsapas, Apostolos
AU  - Tsapas A
AD  - Clinical Research and Evidence-Based Medicine Unit, Second Medical Department, 
      Aristotle University Thessaloniki, Hippokratio General Hospital, 49 
      Konstantinoupoleos Street, 54642, Thessaloniki, Greece. atsapas@auth.gr.
AD  - Diabetes Centre, Second Medical Department, Aristotle University Thessaloniki, 
      Thessaloniki, Greece. atsapas@auth.gr.
AD  - Harris Manchester College, University of Oxford, Oxford, UK. atsapas@auth.gr.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20151229
PL  - United States
TA  - Endocrine
JT  - Endocrine
JID - 9434444
RN  - 0 (Blood Glucose)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Nitriles)
RN  - 0 (Pyrrolidines)
RN  - 9100L32L2N (Metformin)
RN  - I6B4B2U96P (Vildagliptin)
RN  - PJY633525U (Adamantane)
SB  - IM
MH  - Adamantane/*analogs & derivatives/therapeutic use
MH  - Blood Glucose/drug effects/metabolism
MH  - Diabetes Mellitus, Type 2/*drug therapy/epidemiology
MH  - Humans
MH  - Hypoglycemia/chemically induced/epidemiology
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Metformin/therapeutic use
MH  - Nitriles/*therapeutic use
MH  - Pancreatitis/chemically induced/epidemiology
MH  - Pyrrolidines/*therapeutic use
MH  - Treatment Outcome
MH  - Vildagliptin
OTO - NOTNLM
OT  - DPP-4 inhibitors
OT  - Meta-analysis
OT  - Systematic review
OT  - Vildagliptin
EDAT- 2015/12/31 06:00
MHDA- 2017/07/14 06:00
CRDT- 2015/12/31 06:00
PHST- 2015/09/19 00:00 [received]
PHST- 2015/12/19 00:00 [accepted]
PHST- 2015/12/31 06:00 [entrez]
PHST- 2015/12/31 06:00 [pubmed]
PHST- 2017/07/14 06:00 [medline]
AID - 10.1007/s12020-015-0841-1 [pii]
AID - 10.1007/s12020-015-0841-1 [doi]
PST - ppublish
SO  - Endocrine. 2016 Jun;52(3):458-80. doi: 10.1007/s12020-015-0841-1. Epub 2015 Dec 
      29.